| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP Of Clinical Development
1 company
Goldberg Y. Paul is a VP Of Clinical Development at XENE. Recent filings cover 0 purchases and 3 sales. Those positions are worth an estimated $380K at current prices.
Goldberg Y. Paul's largest disclosed position is in XENE as VP Of Clinical Development, worth about $380K. The recent filings there lean toward selling, a net 22,149 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 24, 2015 | XENE Xenon Pharmaceuticals Inc. | VP Of Clinical Development | Sale+OE | 22,149 | $8.88 | $196,664.31 | -32.5% |